278 related articles for article (PubMed ID: 32646393)
1. Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model.
Jackson KD; Higgins CR; Laing SK; Mwila C; Kobayashi T; Ippolito MM; Sylvia S; Ozawa S
BMC Public Health; 2020 Jul; 20(1):1083. PubMed ID: 32646393
[TBL] [Abstract][Full Text] [Related]
2. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
[TBL] [Abstract][Full Text] [Related]
3. Poor-quality antimalarials further health inequities in Uganda.
Evans DR; Higgins CR; Laing SK; Awor P; Ozawa S
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii36-iii47. PubMed ID: 31816072
[TBL] [Abstract][Full Text] [Related]
4. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo.
Ozawa S; Haynie DG; Bessias S; Laing SK; Ngamasana EL; Yemeke TT; Evans DR
Am J Trop Med Hyg; 2019 May; 100(5):1149-1157. PubMed ID: 30675851
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of substandard and falsified antimalarial medications in Nigeria.
Beargie SM; Higgins CR; Evans DR; Laing SK; Erim D; Ozawa S
PLoS One; 2019; 14(8):e0217910. PubMed ID: 31415560
[TBL] [Abstract][Full Text] [Related]
6. Falsified antimalarials: a minireview.
Chaccour C; Kaur H; Del Pozo JL
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):505-9. PubMed ID: 25683870
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Impact of Substandard and Falsified Antimalarials in Benin.
Bui V; Higgins CR; Laing S; Ozawa S
Am J Trop Med Hyg; 2021 Nov; 106(6):1770-7. PubMed ID: 34749311
[TBL] [Abstract][Full Text] [Related]
8. Global scenario of counterfeit antimalarials: A potential threat.
Arora T; Sharma S
J Vector Borne Dis; 2019; 56(4):288-294. PubMed ID: 33269727
[TBL] [Abstract][Full Text] [Related]
9. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.
Renschler JP; Walters KM; Newton PN; Laxminarayan R
Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):119-126. PubMed ID: 25897068
[TBL] [Abstract][Full Text] [Related]
10. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
[TBL] [Abstract][Full Text] [Related]
12. Quality of Artemisinin-based Combination Therapy for malaria found in Ghanaian markets and public health implications of their use.
Tivura M; Asante I; van Wyk A; Gyaase S; Malik N; Mahama E; Hostetler DM; Fernandez FM; Asante KP; Kaur H; Owusu-Agyei S
BMC Pharmacol Toxicol; 2016 Oct; 17(1):48. PubMed ID: 27788677
[TBL] [Abstract][Full Text] [Related]
13. Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches.
Ozawa S; Higgins CR; Nwokike JI; Phanouvong S
Am J Trop Med Hyg; 2022 Jul; 107(1):14-20. PubMed ID: 35895357
[TBL] [Abstract][Full Text] [Related]
14. Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches.
Salami RK; Valente de Almeida S; Gheorghe A; Njenga S; Silva W; Hauck K
Am J Trop Med Hyg; 2023 Aug; 109(2):228-240. PubMed ID: 37339762
[TBL] [Abstract][Full Text] [Related]
15. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
Mori AT; Meena E; Kaale EA
BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
[TBL] [Abstract][Full Text] [Related]
16. Importance of medicine quality in achieving universal health coverage.
Ozawa S; Higgins CR; Yemeke TT; Nwokike JI; Evans L; Hajjou M; Pribluda VS
PLoS One; 2020; 15(7):e0232966. PubMed ID: 32645019
[TBL] [Abstract][Full Text] [Related]
17. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
Petersen A; Held N; Heide L;
PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
[TBL] [Abstract][Full Text] [Related]
18. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Breman JG; Alilio MS; Mills A
Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
[TBL] [Abstract][Full Text] [Related]
19. Counterfeit and substandard malaria drugs in Africa.
Brower V
Lancet Infect Dis; 2017 Oct; 17(10):1026-1027. PubMed ID: 28948928
[No Abstract] [Full Text] [Related]
20. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
